Our listing on the London Stock Exchange in November 2005 marked the beginning of an exciting new phase in the Company’s development. The financial flexibility that we gained through our listing leaves us now very well-positioned to grow our business both organically and through acquisitions.
Our strategy for growth is to build a strong and diverse product portfolio; to expand our geographic reach; to develop and leverage our global research and development capabilities and API sourcing strengths; and to continue to maintain the very high standards of our manufacturing capabilities.
Across our three core businesses – Branded, Generics and Injectables, we have three key strategic aims:
Aim 1: To consolidate our strong market position in the MENA region by launching new products, expanding our geographic reach and increasing market share;
Aim 2: To grow our Injectable business by expanding our product portfolio, developing our manufacturing capabilities and strengthening our sales and marketing network; and,
Aim 3: To continue to pursue profitable growth and maintain significant cash generation in the United States by focusing on high margin, niche product opportunities.
